It has been reported that HOXA-AS3 expression was implicated in the development of small cell lung cancer chemotherapy [28] insensitivity and non-small-cell lung carcinoma cisplatin [29] resistance, knockdown of HOXA-AS3 enhanced the efficacy of chemotherapeutic drugs in lung cancer. Here, PDS5B is linked to lung carcinoma.